InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics, has a couple of milestones to watch in the coming months.
The company's lead drug candidate is Vilobelimab, which is currently in a phase III trial in ulcerative pyoderma gangrenosum. The trial achieved the 30-patient recruitment milestone last November. Interim analysis for trial size adaptation or futility is expected by the end of May 2025. The enrollment period is projected to last at least two years.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com